Navigation Links
Status of the E2007 (perampanel) Development Program
Date:4/10/2008

- Termination of Parkinson's Disease Clinical Development and Focus on

Neuropathic Pain and Epilepsy Indications -

TOKYO, April 11 /PRNewswire/ -- E2007 (perampanel) is a first-in-class, orally administered, highly selective non-competitive AMPA-type glutamate receptor antagonist, in development by Eisai for several indications, including Parkinson's disease, neuropathic pain, epilepsy, multiple sclerosis and migraine prophylaxis.

The AMPA receptor is widely present in almost all excitatory neuronal synapses. It is believed to play a role in a large number of central nervous system (CNS) diseases with different underlying pathophysiology, including neurodegenerative disorders, movement disorders, pain and psychiatric disorders. Eisai has been pursuing development of perampanel for several CNS indications, some of which are currently in Phase II and Phase III. The most advanced indication is Parkinson's disease for which Eisai has been conducting three global Phase III studies (Studies 301, 302 and 309) with perampanel as add-on therapy to levodopa in patients with late-stage disease. Additionally, Eisai is preparing for global Phase III studies for epilepsy and conducting two Phase II studies for neuropathic pain.

Following the completion of the first Phase III Study 301, we recently completed the second Phase III Study 302, which was primarily conducted in North America. Study 302 is a 20-week, double-blind, placebo-controlled study comparing two doses of 2mg and 4mg of perampanel to placebo. The results, compared with placebo, did not show a significant difference in the primary endpoint of reduction of "off" time (time when signs and symptoms of Parkinson's disease return as the effect of levodopa wears off). Perampanel was generally well tolerated. After analyzing the data, Eisai has decided to discontinue the Parkinson's disease program and not pursue regulatory submissions for this indication. Eisai will focus resou
'/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Marital Status Doesnt Affect Lung Cancer Survival
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. Chinese SFDA Grants Immtech Fast Track Status
9. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
10. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
11. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Chindex International, ... ) announced that, at a special meeting of stockholders ... merger agreement (the "Merger  Agreement") by and among the ... Acquisition, Inc. ("Merger Sub"). Parent is an affiliate of ... Ms. Roberta Lipson , the CEO of the ...
(Date:9/16/2014)... Research and Markets has announced the addition of the ... offering. Animal vaccines are biological preparations used ... prepared from weakened or dead microbes that can cause a ... animal vaccines are also formulated using a part of a ... These components act as stimulating agents that trigger ...
(Date:9/16/2014)... 16, 2014 QPID Health , a leader ... headquarters in Boston and their first ... be at 175 Franklin Street in Boston ... QPID Health,s new Southern California office ... expansion will help meet the demands of customers nationwide.  Both ...
Breaking Medicine Technology:Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... Switzerland, June 23 Debiopharm Group,(Debiopharm), a Swiss-based global ... of prescription drugs that target unmet medical,needs, announced that ... was launched in Germany in May 2009, by Dr ... on a preliminary basis in,Belgium. The effective commercial launch ...
... --Whole-Genome Searches Are Revealing Secrets of a Childhood Cancer-- , ... The Children,s Hospital of Philadelphia advance the search for genetic ... childhood cancer. , , Originating in the peripheral nervous ... childhood and causes 15 percent of all childhood cancer deaths. ...
Cached Medicine Technology:Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 3Gene Findings Unlocking Reasons for Neuroblastoma Risk 4
(Date:9/16/2014)... September 16, 2014 Cliff Lake Dental Care ... Kristaleen is the newest dental hygienist to join Dr. Rauchwarter's ... to working with her and knows she will bring many ... , Kristaleen grew up in River Falls, WI. She ... College in 2003 and practiced dental assisting in the Twin ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
(Date:9/16/2014)... CO (PRWEB) September 16, 2014 Aspen ... that it has been recognized for its high morale ... Consulting magazine “The Best Small Firms to Work For ... survey annually, with more than 10,000 consultants participating across ... Extensive employee satisfaction surveys were conducted, and firms were ...
(Date:9/16/2014)... September 14, 2014 A new study found ... (SB) stenting of true coronary bifurcation lesions yields ... The DKCRUSH-VI clinical trial is the first study ... Findings were reported today at the 26th annual ... the Cardiovascular Research Foundation (CRF), TCT is the ...
(Date:9/16/2014)... with endocrine therapy and radiation therapy as part ... care for women with hormone-receptor positive (HR+) invasive ... Fox Chase Cancer Center, however, shows that combination ... with the disease. , The results, which ... for Radiation Oncology,s 56th Annual Meeting on Sunday, ...
Breaking Medicine News(10 mins):Health News:Cliff Lake Dental Care Announces Newest Team Member 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3
... patients covered by compensation have worse physical and life-quality ... to new research. ,Orthopaedic injury, usually ... form of hospitalisation in Australia, according to the study ... ,,The authors Professor Peter Cameron, Head of ...
... health doctors argue for routine opt-out HIV testing in ... departments and hospital wards. ,In the first article, ... people in the UK with HIV do not know they ... for pregnant women and people attending genitourinary (GUM) clinics. ...
... taken before meals, can improve blood glucose control for people ... with short-acting injected insulin that is taken in addition ... according to a new review of the body of published ... 2 diabetes typically have to take extra insulin at mealtimes ...
... AVGO), a late stage biotechnology company that develops central ... selection of the optimal dose of HD-02, its ... ,This dose was determined in an open-label ... Dr. Diana Rosas of Massachusetts General Hospital (MGH), and ...
... mass displacement of people in sub-Saharan Africa do not necessarily ... refugee agency said on Friday. ,Contradicting a ... the UN High Commissioner for Refugees (UNHCR) said that out ... actually had a lower rate than surrounding host communities. ...
... who was detained for 30 years in his native Cuba, realized ... a ceremony in Miami. ,Now, he says, his ... the former fisherman is convinced he will outlive the ailing Cuban ... far less healthy than I am, he can hardly talk," Temprana ...
Cached Medicine News:Health News:Doctors Call for Opt-out Approach to HIV Testing 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 3Health News:Avicena to Advance Huntington's Disease Clinical Program into Phase III 2Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2
... intended for the immunochromatographic, qualitative determination ... Strip Gonorrhea is based on the ... determination of gonorrhea antigen in the ... system as an aid in the ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy....
Medicine Products: